Modern vaccine strategies for emerging zoonotic viruses

Ahmed, Atif; Safdar, Muhammad; Sardar, Samran; Yousaf, Sahar; Farooq, Fiza; Raza, Ali; Shahid, Muhammad; Malik, Kausar; Afzal, Samia

doi:10.1080/14760584.2022.2148660

Cited by 3 publications

(1 citation statement)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As viruses are constantly emerging from zoonotic origin, vaccines seem to be the most effective therapeutic option to reduce the incidence of disease ( Ahmed et al, 2022 ). Different vaccines are under development against hantaviruses to improve protective efficacy and safety profiles ( Saavedra et al, 2021 ).…”

Section: Vaccines and Immunotherapymentioning

confidence: 99%

Hantavirus: an overview and advancements in therapeutic approaches for infection

Afzal,

Ali,

Batool

et al. 2023

Front. Microbiol.

Self Cite

View full text Add to dashboard Cite

Hantaviruses are a significant and emerging global public health threat, impacting more than 200,000 individuals worldwide each year. The single-stranded RNA viruses belong to the Hantaviridae family and are responsible for causing two acute febrile diseases in humans: Hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS). Currently, there are no licensed treatments or vaccines available globally for HTNV infection. Various candidate drugs have shown efficacy in increasing survival rates during the early stages of HTNV infection. Some of these drugs include lactoferrin, ribavirin, ETAR, favipiravir and vandetanib. Immunotherapy utilizing neutralizing antibodies (NAbs) generated from Hantavirus convalescent patients show efficacy against HTNV. Monoclonal antibodies such as MIB22 and JL16 have demonstrated effectiveness in protecting against HTNV infection. The development of vaccines and antivirals, used independently and/or in combination, is critical for elucidating hantaviral infections and the impact on public health. RNA interference (RNAi) arised as an emerging antiviral therapy, is a highly specific degrades RNA, with post-transcriptional mechanism using eukaryotic cells platform. That has demonstrated efficacy against a wide range of viruses, both in vitro and in vivo. Recent antiviral methods involve using small interfering RNA (siRNA) and other, immune-based therapies to target specific gene segments (S, M, or L) of the Hantavirus. This therapeutic approach enhances viral RNA clearance through the RNA interference process in Vero E6 cells or human lung microvascular endothelial cells. However, the use of siRNAs faces challenges due to their low biological stability and limited in vivo targeting ability. Despite their successful inhibition of Hantavirus replication in host cells, their antiviral efficacy may be hindered. In the current review, we focus on advances in therapeutic strategies, as antiviral medications, immune-based therapies and vaccine candidates aimed at enhancing the body’s ability to control the progression of Hantavirus infections, with the potential to reduce the risk of severe disease.

show abstract

Section: Vaccines and Immunotherapymentioning

confidence: 99%

Hantavirus: an overview and advancements in therapeutic approaches for infection

Afzal,

Ali,

Batool

et al. 2023

Front. Microbiol.

Self Cite

View full text Add to dashboard Cite

show abstract

Monkeypox pandemic containment: does the ACAM2000 vaccine play a role in the current outbreaks?

Katamesh

Madany

Labieb

et al. 2023

Expert Review of Vaccines

View full text Add to dashboard Cite

Preventive Practices of Hantavirus in a Rural Community in Panama: An Explanatory Sequential Mixed Methods Study

Agrazal García,

Gordón de Isaacs,

Escalante-Barrios

et al. 2024

J Transcult Nurs

View full text Add to dashboard Cite

Introduction: Preventive care practices are a challenge in community care. This study examined hantavirus preventive practices and their relationship with personal and social factors, lifestyle, and cultural beliefs. Method: An explanatory sequential mixed methods design, guided by Leininger’s Theory of Culture Care Diversity and Universality, was used in two phases: (a) a cross-sectional relational design ( n = 109) and (b) ethnonursing research ( n = 30), in an endemic community in Panama. Univariate and bivariate analyses were used to analyze the quantitative data, whereas the Leininger’s analysis model was used to analyze the qualitative data. Results: In the quantitative phase, the most frequent preventive practice was household hygiene, and the least frequent was vector control. Two of the eight preventive practices were associated with personal factors and two were associated with social factors. In the qualitative phase, lifestyle, beliefs, and context were found to influence the adoption of hantavirus preventive practices and help explain the quantitative findings. Discussion: Knowledge and understanding of the social and cultural contexts are essential for hantavirus prevention.

show abstract

Modern vaccine strategies for emerging zoonotic viruses

Cited by 3 publications

References 102 publications

Hantavirus: an overview and advancements in therapeutic approaches for infection

Hantavirus: an overview and advancements in therapeutic approaches for infection

Monkeypox pandemic containment: does the ACAM2000 vaccine play a role in the current outbreaks?

Preventive Practices of Hantavirus in a Rural Community in Panama: An Explanatory Sequential Mixed Methods Study

Contact Info

Product

Resources

About